News headlines about Catalent (NYSE:CTLT) have trended somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Catalent earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.0728496158994 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern’s scoring:
- William Blair Analysts Boost Earnings Estimates for Catalent Inc (CTLT) (americanbankingnews.com)
- Catalent Inc (CTLT) Expected to Post Earnings of $0.34 Per Share (americanbankingnews.com)
- Q2 2018 EPS Estimates for Catalent Inc (CTLT) Cut by William Blair (americanbankingnews.com)
- Catalent (CTLT) & Valeant Pharmaceuticals Intl (VRX) Critical Analysis (americanbankingnews.com)
- Zacks Investment Research Upgrades Catalent (CTLT) to Hold (americanbankingnews.com)
Catalent (CTLT) traded up $0.60 during midday trading on Friday, reaching $43.00. 549,834 shares of the company were exchanged, compared to its average volume of 664,556. Catalent has a 1-year low of $25.51 and a 1-year high of $43.39. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. The stock has a market capitalization of $5,630.00, a P/E ratio of 50.00, a PEG ratio of 2.68 and a beta of 1.41.
Several analysts have recently commented on the stock. BidaskClub downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, September 15th. Bank of America reiterated a “buy” rating and issued a $45.00 target price (up previously from $40.00) on shares of Catalent in a report on Wednesday, September 20th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 target price for the company in a report on Monday, November 6th. Wells Fargo & Co increased their target price on shares of Catalent from $39.00 to $43.00 and gave the company an “outperform” rating in a report on Wednesday, September 20th. Finally, ValuEngine downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $44.44.
In related news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Uwe Roehrhoff acquired 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average price of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. Company insiders own 1.70% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
What are top analysts saying about Catalent? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catalent and related companies.